Global Eosinophilic Esophagitis Drug Revenue Is Nearly 103 M USD In 2017
Wednesday, 31 Oct, 2018
In the last several years, global market of eosinophilic esophagitis drug developed smoothly, with an average growth rate of 3.73%. In 2017, global revenue of eosinophilic esophagitis drug is nearly 103 M USD.

The classification of eosinophilic esophagitis drug includes budesonide, fluticasone and other types, and the proportion of budesonide in 2017 is about 52%.

North America is the largest consumption region of eosinophilic esophagitis drug, with a sales market share nearly 32% in 2017. Europe is the second largest consumption region of eosinophilic esophagitis drug, enjoying Sales market share nearly 29% in 2017.

Market competition is intense. AstraZeneca, GSK, Bayer are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.

For developing product, there are 2 products in Phase 3; 4 products in Phase 2 and 2 products in Preclinical. SHP621 and Budesonide effervescent tablets are in Phase 3, and they are owned by Dr. Falk Pharma and Shire.